VEXAS syndrome: favourable clinical and partial haematological responses to subcutaneous abatacept therapy with 30-month follow-up.

In the article, the authors present a case of a 71-year-old man who was presented to a clinic due to generalized rash, fatigue, and night sweats to discuss the condition called vacuoles, E-1 ubiquitin activating enzyme, X-linked autoinflammatory and somatic (VEXAS) syndrome and the effectiveness of of subcutaneous abatacept therapy as treatment. Also cited are the patient's symptoms like ocular, nasal and auricular inflammation.